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Abstract — Video capsule endoscopy is a widely accepted 
clinical alternative to conventional endoscopy for examination of 
the gastrointestinal tract. Its advantages are that it can visualize 
the entire gastrointestinal tract including the anatomically 
remote small intestine and it is less invasive for the patient as 
compared to conventional endoscopy. However, video capsule 
endoscopy is suitable only for diagnosis, with little research into 
therapeutic capsule endoscopy. Like video capsule endoscopy, 
therapeutic capsule endoscopy has great potential to reach 
locations that would previously have been difficult, such as the 
small intestine. Ultrasound-mediated targeted drug delivery is a 
promising therapeutic capsule based modality as it may be scaled 
to size, provides temporary gut barrier disruption and power 
requirement is relatively low.    
This paper investigates the feasibility of a therapeutic capsule 
endoscope utilizing ultrasound-mediated targeted drug delivery. 
A prototype device, SonoCAIT, was built and tested. Further 
investigation of the drug delivery capabilities of the miniature 
focused US sources, testing was carried out on an in vitro model 
replicating the lining of the small intestine. This involved 
measuring the transepithelial resistance, a measure for barrier 
function, during insonation. A drop in transepithelial resistance 
occurred during insonation and returned to starting value post 
insonation. In anticipation of in vivo work, SonoCAIT, was 
reconfigured to operate within the small bowel of pigs. 
Keywords — Capsule Endoscopy; UmTDD; SonoCAIT; 
Therapeutic Capsule Endoscope; GI Therapy 
I.  INTRODUCTION 
Gastrointestinal (GI) diseases, such as inflammatory bowel 
disease (IBD), are an increasingly major health problem 
worldwide [1]. Crohn’s disease, a subset of IBD, is a chronic, 
relapsing-remitting inflammatory disorder affecting the entire 
GI Tract.  
Despite the role of the GI tract as a conduit for nutrient 
entry, GI epithelia can distinguish between beneficial and 
harmful agents. Current therapeutic agents used for treatment 
of Crohn’s range from steroids to highly potent biological 
agents administered orally or intravenously and can be 
associated with unwanted side effects. Delivering drugs locally, 
to the diseased region presents a means for reduced systemic 
effects. In addition, delivering drugs beyond the GI epithelia 
could increase drug uptake and hence effectiveness. 
Crohn’s disease occurs most often in the small intestine, 
predominately at the ileocecal junction. However, Crohn’s can 
manifest panenterically, making diagnosis via endoscopy more 
complex since this standard technique cannot visualize the 
entire small intestine. A promising alternative that allows 
visualization of the entire GI tract is video capsule endoscopy 
(VCE). VCE involves ingesting an autonomous capsule 
containing video imaging and wireless communications. 
Therefore, it can visualize the entire GI tract, reduce stress on 
the patient since it is less invasive than endoscopy, and reduce 
costs since it does not require a skilled operator to control [2].  
There have been multiple examples of capsule endoscopes 
developed for therapy by acting as drug delivery vehicles. 
Prominent examples of such devices are Intelisite [3] and 
Enterion [4]. These capsules contained drug reservoir with 
capacity of 1 ml that can be emptied remotely. However, 
neither capsule can deliver drugs across the GI epithelium, 
limiting their efficacy. A capsule was developed that contained 
a microneedle for delivery through the mucosa [5] however, 
like the Enterion and Intelisite capsules, it cannot be positioned 
or localised and the microneedle poses a risk of perforating the 
mucosa. This could cause further problems, such as a breach in 
the GI epithelium, which would allow bacterial invasion. 
US-mediated targeted drug delivery (UmTDD) is a means 
to overcome some of the challenges associated with therapeutic 
capsule endoscopy (TCE). UmTDD allows therapeutic agents 
to be delivered directly to the treatment site, reducing 
unwanted systemic effects, and uses focused US to direct, 
release, and enhance uptake of the therapeutic agents [6-8]. 
Typically, focused US transducers used for UmTDD are large 
arrays and extracorporeal. An example of UmTDD used in this 
configuration is for the treatment of uterine fibroids [9]. In this 
configuration, the US beam could be disrupted by gas pockets 
and bone, with guidance often required, using magnetic 
resonance for instance. This results in the procedure becoming 
highly complex and expensive. A potential solution to this 
would be to contain an UmTDD system in a capsule 
endoscope. UmTDD could solve some of the problems 
associated with other TCEs by allowing drugs to be delivered 
through the GI epithelium, potentially improving treatment. 
However, despite the immense potential of UmTDD capsules 
challenges remain that include: miniaturising the US 
transducers to fit within a capsule; ensuring the miniature 
transducers can enhance uptake; and positioning the capsules 
so they are directed towards the treatment site.  
This paper sets out to address some of these challenges. A 
prototype therapeutic capsule, SonoCAIT, was constructed and 
benchtop testing has been carried out, discussed in section II. 
In section III, testing of the miniature focused US sources used 
in SonoCAIT on appropriate in vitro models of the small 
intestine to determine if they can enhance drug uptake is 
described. In section IV, the reconfiguration of SonoCAIT is 
described so that it is suitable for translational use and the next 
steps towards in vivo trials are discussed. 
II. PROTOTYPE THERAPEUTIC CAPSULE ENDOSCOPE: 
SONOCAIT 
A. Capsule Construction 
The Capsule has four main components necessary for 
UmTDD: focused US transducer, drug delivery channel, video 
camera and light source. The focused US source consisted of a 
self-focusing PZ26 (Meggitt Sensing Systems, Kvistgaard, 
Denmark) bowl with outer diameter OD = 5 mm, radius of 
curvature RC = 15 mm, and frequency f = 4 MHz. The backing 
layer consisted of microballoon loaded epoxy (Epofix, Struers 
A/S, Denmark) and the transducer consisted of a case produced 
by additive manufacturing (Stratysis Ltd., MN, USA). The 
detailed fabrication process is discussed by Stewart et al [6]. 
The drug delivery channel consisted of a fine bore polythene 
tubing with outer diameter OD = 0.96 mm and inner diameter 
ID = 0.58 mm. Video imaging was provided by a CMOS 
camera (microScoutCamTM, Medigus Ltd., Israel) with outer 
diameter OD = 1.2 mm and length L = 5 mm. The camera has 
an imaging area of 492.8 ?m x 488.4 ?m and corresponding 
resolution of 220 x 224 pixels. The camera was connected to a 
video processor which captures and saves imaging data. 
Illumination was provided for the camera by utilizing a printed 
circuit board (PCB) with four 40 mW (OSRAM Opto 
Semiconductors GmbH, Germany). The PCB has a 1.5 mm 
diameter hole in the center to allow the camera to pass through.  
The prototype capsule, SonoCAIT, was initially tethered to 
provide power and therapeutic agent delivery. The tether that 
was chosen for the prototype capsule has an outer diameter OD 
= 2.25 mm and inner diameter ID = 1.65 mm and houses power 
cables for camera and illumination and drug delivery channel. 
The capsule shell was designed in SolidWorks (Dassault 
Systemes SOLIDWORKS Corp., Waltham, MA) and produced 
by additive manufacturing using an Objet Connex 500 printer 
(Stratasys Ltd., Minnesota, USA). A computer-aided drawing 
of the prototype capsule and components is shown in Fig.1. 
below. 
B. Benchtop Testing 
Benchtop testing was carried out to characterize the ability 
of the miniature focused US sources to direct microbubbles 
(MBs) towards the target location (i.e. towards the US focus). 
The capsule was configured as shown in Fig.1. and MBs were 
passed through the delivery channel and into the US field. The 
behavior of the MBs was monitored via the video camera. It 
was found that the stream of MBs was redirected by more than 
90o by the acoustic radiation forces of the focused US. This 
result was important because it showed that the focused US 
transducer can direct MBs (that could be loaded together with 
therapeutic agents) towards the targeted location. Further 
details of the benchtop testing are described in [10]. 
III. MEASURING THE EFFECTS OF FOCUSED ULTRASOUND ON 
SMALL INTESTINE CELL MODEL 
This section investigates the effectiveness of the miniature 
focused US sources at enhancing drug uptake through the GI 
barrier. 
A. Materials and Methods 
Cultured human colon cancer cells (Caco-2) form a model 
of the small intestine once differentiated and polarized. They 
mimic enterocytes lining the small intestine, and form cellular 
junctions and microvilli [11]. Consequently, Caco-2 cells are 
widely accepted in the literature and are a food and drug 
administration (FDA) approved model of the small intestine for 
drug transport studies.  
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Fig.1. Computer aided cross sectional drawing of SonoCAIT. Capsule 
contains drug delivery channel, video camera and illumination, and 
focused US transducer. 
Caco-2 cells were maintained in appropriate cell media and 
cultured under aseptic conditions. Cells were seeded on 
suspended membranes (ThinCert, Greiner Bio-One, 
Kremunster, Austria) at 500,000 cells per 12-well ThinCert. 
They were grown for 21-25 days until fully differentiated and 
polarized where the small intestinal model is established. 
To perform experiments on the cell model, an insonation 
system was used [10] that matched transducers in SonoCAIT, 
with the exception that the delivery channel is now integrated 
and passes through the center of the transducer. This 
configuration minimizes the footprint of the UmTDD 
components and saves space in future iterations of SonoCAIT. 
Cells were insonated with a continuous sinusoidal waveform 
for 60s and an amplitude of 10 Vpp, corresponding to a pressure 
of 150 kPa. Transepithelial resistance (TER), a measure of cell 
barrier function [12], was measured during and post insonation. 
Microbubbles (SonoVue, Bracco S.p.A., Milan, Italy) were 
introduced through the delivery channel of the transducer at a 
rate of 30 ml per hour at a concentration of 2x106 MBs/ml 
diluted in cell media. Each experiment was performed in 
triplicate. Controls included: MBs introduced through the 
delivery channel, with no US present; and US only, with no 
MBs present.  
B. Results 
Results are displayed in Fig.2. The MB and US samples 
showed a drop in TER approximately ten times greater than 
controls. Since TER is a measure of epithelial barrier function, 
such increased drop in TER could translate into enhanced 
uptake of drugs through the mucosal barrier. However, further 
experiments are necessary to determine the exact relationship 
between reduced TER and increased drug uptake. In all 
samples, TER returned to starting values approximately 3 
minutes post insonation. Such a temporary reduction in barrier 
function means the risk of bacterial invasion is minimal.  
IV. PROGRESS TOWARDS IN VIVO TRIALS 
The next step involves moving toward testing the capsule in 
vivo. Fluorescent particles will be delivered using SonoCAIT 
and the effectiveness of the on-board transducers at enhancing 
uptake will be assessed. Fluorescent particles will be utilized 
because they allow quick post experimental analysis via 
fluorescent illumination and are cost effective. 
The following section describes the reconfiguration of 
SonoCAIT to make it suitable for use in vivo and describes the 
future experiments it will be used for.  
A. SonoCAIT Reconfiguration and Construction 
The main components in SonoCAIT are the drug delivery 
channel and focused US transducer; however, it lacks a means 
to measure uptake of the fluorescent particles. This will be 
achieved using the fluorescent imaging capsule developed by 
Al-Rawhani et al [13]. Therefore, SonoCAIT only needs to 
contain drug delivery channel and focused US components and 
can remain tethered. This allows in vivo testing to be performed 
earlier than previously anticipated. Future versions of 
SonoCAIT will combine modalities from both capsules. 
The capsule was designed in SolidWorks (Dassault 
Systemes SOLIDWORKS Corp., Waltham, MA) and printed 
using an Objet Connex 500 (Stratasys Ltd., Minnesota, USA). 
The capsule is printed in two halves to allow easier assembly 
and recessed grooves lock the two halves together. The 
transducer was constructed in the same process outlined by 
Stewart et al [10]. It was necessary that the tether is flexible 
enough so that it does not damage or deform the bowel but also 
have a large enough inner diameter that it can contain drug 
delivery and power cables. To achieve this, a GI feeding tube 
was used (CORPAK MedSystems, IL, USA) that has OD = 4 
mm, ID = 2.65 mm, and L = 1.4 m. As they are designed for 
use in vivo they are flexible and CE marked. Finally, the 
capsules and tether were parylene coated to provide 
biocompatibility and to reduce friction. The reconfigured 
capsule is shown in Fig.3.. 
B. Future Experiments Using SonoCAIT 
Experiments will be carried out as part of a study approved 
by the Animal Welfare and Ethical Review Board of the Roslin 
Institute, Roslin, Midlothian, EH25 9RG and are being carried 
out under Home Office (UK) License PPL 7008812. 
The aim is to determine if UmTDD is feasible in vivo and if 
it can enhance uptake. The capsule will first be inserted into the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.(a) Front view of the in vivo reconfiguration of SonoCAIT. 
Transducer and drug delivery channel are shown, along with tether to 
provide power and delivery. (b) Side view. Capsule is 11 mm diameter 
by 30 mm in length, similar in size to commercial capsule endoscopes. 
 
 
Fig. 2. TER drop, as a percentage of original resistance, of the Caco-2 cell 
model during insonation. Controls included MB only and US only. The 
MB+US sample showed a ten times greater drop in TER than the US 
Only. 
(a) (b) 
10 mm 
porcine small bowel. The small bowel will be insonated, and 
fluorescent particles will be introduced. The fluorescence 
imaging capsule will then be administered into the small bowel 
and it will assess uptake. Post mortem, the small bowel tissue 
will be investigated visually and by histology. 
V. CONCLUSION AND FUTURE WORK 
This paper described the development and testing of a 
therapeutic capsule endoscope utilizing UmTDD.  
In summary, the prototype capsule showed it was possible 
to fit an UmTDD system into capsule endoscope format. It was 
shown that this configuration could redirect a stream of MBs 
towards the treatment site. The effectiveness of the miniature 
focused US transducers at enhancing drug uptake was 
investigated on a small bowel cell model. Reduced barrier 
function was observed during insonation, which could translate 
to enhanced intercellular drug uptake. Finally, the 
reconfiguration of SonoCAIT to make it suitable for in vivo use 
was discussed. Future work involving this capsule was 
described and will include measuring the uptake of fluorescent 
particles delivered by the capsule into porcine small bowel and 
assessing their uptake into tissue with a fluorescence imaging 
capsule and post mortem via histology. This work shows that 
UmTDD as a modality for TCE is feasible could provide 
immense clinical benefit for treatment of GI diseases such as 
Crohn’s disease. 
Initially tethered, to facilitate delivery power and reagents, 
future versions will include wireless communications and 
power delivery. This could be achieved by embedding an 
antenna in the capsule shell to maximize space within the 
capsule [14]. In addition, future capsules will combine 
positioning and localization functionality to allow precise 
spatial targeting of reagents. This could be achieved by 
controlling the capsule with magnets, similar to Slawinski et al 
[15] who use a magnetic robotic arm to propel a capsule 
endoscope. Future work will aim to combine the UmTDD 
system described in this paper with fluorescence imaging, 
wireless communications and positioning/localization facilities 
to allow fully autonomous therapy in the GI tract.    
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